2. Search Result
Search Result
Results for "

Hepatocellular carcinoma tumor

" in MedChemExpress (MCE) Product Catalog:

54

Inhibitors & Agonists

1

Screening Libraries

5

Peptides

4

Inhibitory Antibodies

12

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0462
    Corilagin
    5+ Cited Publications

    		 Toll-like Receptor (TLR) Reverse Transcriptase Bacterial Apoptosis Autophagy Infection Inflammation/Immunology Cancer
    Corilagin, a gallotannin, has anti-tumor, anti-inflammatory and hepatoprotective activities. Corilagin inhibits activity of reverse transcriptase of RNA tumor viruses. Corilagin also inhibits the growth of Staphylococcus aureus with a MIC of 25 μg/mL. Corilagin shows anti-tumor activity on hepatocellular carcinoma and ovarian cancer model. Corilagin shows low toxicity to normal cells and tissues .
    Corilagin
  • HY-N0462R
    Corilagin (Standard)

    		Toll-like Receptor (TLR) Reference Standards Reverse Transcriptase Bacterial Apoptosis Autophagy Infection Inflammation/Immunology Cancer
    Corilagin (Standard) is the analytical standard of Corilagin. This product is intended for research and analytical applications. Corilagin, a gallotannin, has anti-tumor, anti-inflammatory and hepatoprotective activities. Corilagin inhibits activity of reverse transcriptase of RNA tumor viruses. Corilagin also inhibits the growth of Staphylococcus aureus with a MIC of 25 μg/mL. Corilagin shows anti-tumor activity on hepatocellular carcinoma and ovarian cancer model. Corilagin shows low toxicity to normal cells and tissues .
    Corilagin (Standard)
  • HY-153863
    MS934

    		PROTACs MEK Raf Cancer
    MS934 is a novel improved VHL-recruiting MEK 1/2 PROTAC degrader. MS934 also degrades CRAF. MS934 can be used for the research of variety of human cancers, such as melanoma, nonsmall cell lung cancer (NSCLC), colorectal cancer, primary brain tumors, and hepatocellular carcinoma (Pink: Target protein ligand (HY-168288); Black: linker (HY-168289); Blue: E3 ligase ligand (HY-112078)) .
    MS934
  • HY-N10926
    (+)-Glaucarubinone

    		AP-1 MMP p38 MAPK PERK Cadherin Cancer
    (+)-Glaucarubinone is a quassinoid compound and a potent activator protein-1 (AP-1) inhibitor with an EC50 value of 0.13 µM. (+)-Glaucarubinone has anti-tumor activity and can be used in the research of tumors such as hepatocellular carcinoma .
    (+)-Glaucarubinone
  • HY-N0754
    Eupalinolide A

    		YAP HSP Reactive Oxygen Species (ROS) ERK Autophagy Apoptosis Inflammation/Immunology Cancer
    Eupalinolide A is a Yes-associated protein (YAP) degrader and HSP70 inducer. Eupalinolide A inhibits osteogenic differentiation of tendon-derived stem cells (TDSCs). Eupalinolide A induces autophagy in hepatocellular carcinoma cells via activating the ROS/ERK signaling pathway. Eupalinolide A protects PAM212 cells from UVB-, Menadione (HY-B0332)-, or heat shock-induced apoptosis. Eupalinolide A alleviates trauma-induced heterotopic ossification (HO) of Achilles tendon and inhibits growth of MHCC97-L and HCCLM3 hepatocellular carcinoma xenograft tumors in mice. Eupalinolide A can be used for the study of traumatic heterotopic ossification of tendons and hepatocellular carcinoma .
    Eupalinolide A
  • HY-N2232
    N-​Feruloyloctopamine

    N-trans-Feruloyloctopamine

    		 Akt p38 MAPK Apoptosis Cadherin Cancer
    N-Feruloyloctopamine (N-trans-Feruloyloctopamine) is an antioxidant component that can be isolated from garlic skin. N-Feruloyloctopamine can inhibit tumor cell proliferation and invasion, and induce apoptosis. N-Feruloyloctopamine has antitumor activity and can be used in the research of tumors such as hepatocellular carcinoma .
    N-​Feruloyloctopamine
  • HY-131704
    FGFR4-IN-5

    		FGFR Cancer
    FGFR4-IN-5 is a potent and selective covalent FGFR4 inhibitor with an IC50 of 6.5 nM. FGFR4-IN-5 exhibits strong anti-tumor activity in vivo and can be used for hepatocellular carcinoma research .
    FGFR4-IN-5
  • HY-P11050A
    SP94

    		Apoptosis Cancer
    SP94 is a peptide ligand with high specificity for hepatocellular carcinoma cells. SP94 selectively binds to multiple hepatocellular carcinoma cell lines in vitro. SP94 inhibits tumor growth in a mouse model of hepatocellular carcinoma by promoting apoptosis and reducing angiogenesis. SP94 can be used as a specific probe for hepatocellular carcinoma imaging. SP94 is useful for hepatocellular carcinoma research .
    SP94
  • HY-P991566
    KD6001

    		CTLA-4 Cancer
    KD6001 is a humanized IgG1κ monoclonal antibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC50: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer .
    KD6001
  • HY-P10832
    ATWLPPRAANLLMAAS

    		Apoptosis Ras Raf MEK ERK Caspase PARP Bcl-2 Family Cancer
    ATWLPPRAANLLMAAS is a chimeric peptide with anti-angiogenic and potent anti-tumor effects. ATWLPPRAANLLMAAS can inhibit the proliferation, viability, migration, and invasion of human hepatocellular carcinoma cells, and induce apoptosis. .
    ATWLPPRAANLLMAAS
  • HY-W478417
    (R)-Etodolac

    		β-catenin Cancer
    (R)-Etodolac is an enantiomer of the non-steroidal anti-inflammatory drug etodolic acid (HY-76251), which can inhibit the transcriptional inhibition of β-catenin. (R)-Etodolac has anti-tumor activity and can be used in the research of hepatocellular carcinoma .
    (R)-Etodolac
  • HY-N6623
    Malvidin-3-galactoside chloride
    1 Publications Verification

    		 Apoptosis Endogenous Metabolite Reactive Oxygen Species (ROS) Cancer
    Malvidin-3-galactoside chloride, an anthocyanin monomer, induces hepatocellular carcinoma (HCC) cells cycle arrest and apoptosis. Malvidin-3-galactoside chloride inhibits the production and accumulation of ROS. Malvidin-3-galactoside chloride has anti-tumor function .
    Malvidin-3-galactoside chloride
  • HY-100492
    Fisogatinib
    4 Publications Verification

    BLU-554

    		 FGFR Cancer
    Fisogatinib (BLU-554) is a potent, highly selective and orally active fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC50 of 5 nM. Fisogatinib has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signalling .
    Fisogatinib
  • HY-163301
    Antitumor agent-139

    		Reactive Oxygen Species (ROS) Cancer
    Antitumor agent-139 (compound 9b) is a liver - and mitochondria-targeting gold(I) complexe, and produces reactive oxygen species (ROS) and facilitates DNA excretion. Antitumor agent-139 inhibits tumor growth in a patient-derived xenograft model of hepatocellular carcinoma .
    Antitumor agent-139
  • HY-177134
    Taligantinib

    		VEGFR c-Met/HGFR Cancer
    Taligantinib (Compound Example 70) is an orally active and selective dual inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) and hepatocyte growth factor receptor (c-Met). Taligantinib suppresses tumor angiogenesis and cell proliferation. Taligantinib is promising for research of solid tumors such as non-small cell lung cancer and hepatocellular carcinoma .
    Taligantinib
  • HY-16232
    Glufosfamide

    D 19575; Glucosylifosfamide mustard

    		 Apoptosis Caspase Bcl-2 Family Cancer
    Glufosfamide is a glucose-conjugated alkylating cytotoxic agent and a derivative of Ifosfamide (HY-17419). Glufosfamide induces apoptosis frequency and increase the expression of caspase-9 and caspase-3 in cancer cells. Glufosfamide shows great anti-tumor activity in MiaPaCa-2-RFP mouse model. Glufosfamide can be used for the study of hepatocellular carcinoma, prostate cancer and pancreatic carcinoma .
    Glufosfamide
  • HY-P99052
    Tislelizumab
    3 Publications Verification

    BGB-A317

    		 PD-1/PD-L1 Inflammation/Immunology Cancer
    Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .
    Tislelizumab
  • HY-P10553
    ARF(26–44), cell-permeable

    		Apoptosis Cancer
    ARF(26–44), cell-permeable is a cell-penetrating peptide derived from a specific amino acid sequence of the p14ARF tumor suppressor protein. As a functional inhibitor of FoxM1, ARF(26–44) cell-permeable shows significant anti-tumor activity in the treatment of mouse hepatocellular carcinoma (HCC), significantly increasing tumor cell apoptosis and reducing tumor cell proliferation and angiogenesis. ARF(26–44), cell-permeable can be used in research on tumor therapy .
    ARF(26–44), cell-permeable
  • HY-176508
    KDX1381

    		Casein Kinase Cancer
    KDX1381 is a bivalent CK2α inhibitor (IC50: 17 nM, KD: 54 nM). KDX1381 has antitumor activity in mouse 786-O and A375 tumor xenograft models. KDX1381 combined with VEGFR inhibitors or DNA damaging agents enhances antitumor efficacy in mouse hepatocellular carcinoma and glioma models .
    KDX1381
  • HY-P99013
    Codrituzumab
    1 Publications Verification

    GC33; RO5137382

    		 Glycoprotein VI Cancer
    Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .
    Codrituzumab
  • HY-150072
    DS89002333

    		PKA Cancer
    DS89002333 is an orally active and potent PRKACA inhibitor, with an IC50 of 0.3 nM. DS89002333 shows good anti-tumor activity in an FL-HCC patient-derived xenograft model (expressing the DNAJB1-PRKACA fusion gene). DS89002333 can be used in study of fibrolamellar hepatocellular carcinoma (FL-HCC) .
    DS89002333
  • HY-178098
    TEAD-IN-21

    		YAP Cancer
    TEAD-IN-21 is a potent and orally active pan-TEAD inhibitor with an IC50 of 3 nM. TEAD-IN-21 effectively inhibited the proliferation of Huh-7 cells. TEAD-IN-21 selectively downregulates TEAD-dependent downstream genes. TEAD-IN-21 achieves tumor regression in a liver cancer-derived tumor xenograft mice model. TEAD-IN-21 can be used in the research of hepatocellular carcinoma (HCC) .
    TEAD-IN-21
  • HY-16232R
    Glufosfamide (Standard)

    		Reference Standards Apoptosis Bcl-2 Family Caspase Cancer
    Glufosfamide (Standard) is the analytical standard of Glufosfamide. This product is intended for research and analytical applications. Glufosfamide is a glucose-conjugated alkylating cytotoxic agent and a derivative of Ifosfamide (HY-17419). Glufosfamide induces apoptosis frequency and increase the expression of caspase-9 and caspase-3 in cancer cells. Glufosfamide shows great anti-tumor activity in MiaPaCa-2-RFP mouse model. Glufosfamide can be used for the study of hepatocellular carcinoma, prostate cancer and pancreatic carcinoma .
    Glufosfamide (Standard)
  • HY-N7073
    Silymarin
    Maximum Cited Publications
    9 Publications Verification

    		 SARS-CoV Infection Neurological Disease Inflammation/Immunology Cancer
    Silymarin is an extract of the milk thistle (Silybum marianum). Silymarin is an effective SARS-CoV-2 main protease (M pro) inhibitor. Silymarin can significantly reduce tumor cell proliferation, angiogenesis as well as insulin resistance. Silymarin has the chemopreventive effect on hepatocellular carcinoma (HCC). Silymarin has the potential for COVID-19 research .
    Silymarin
  • HY-175265
    PQ32

    		c-Myc Ras Apoptosis Cancer
    PQ32 is an antitumor agent that targets c-MYC Pu27 and KRAS G-quadruplexes. PQ32 inhibits tumor cell proliferation, arrests the cell cycle at the G2 phase, and induces apoptosis. PQ32 inhibits the expression of c-MYC and KRAS genes. PQ32 can inhibit tumor growth in mice and is used in the study of lymphoma, breast cancer, lung cancer, hepatocellular carcinoma, colorectal cancer, and other cancers .
    PQ32
  • HY-178140
    STAT3-IN-47

    		STAT Cancer
    STAT3-IN-47 is an orally active STAT3 inhibitor. STAT3-IN-47 exhibits broad-spectrum anti-tumor activity against HeLa, HepG2, U87, and LN229 cells. STAT3-IN-47 suppresses STAT3 activation in vitro. STAT3-IN-47 can be used for the study of solid tumors, especially central nervous system (CNS) malignancies and hepatocellular carcinoma .
    STAT3-IN-47
  • HY-19345
    Vacquinol-1

    NSC13316

    		 p38 MAPK Cancer
    Vacquinol-1 (NSC13316) is a MKK4-specific activator that activates MAPK pathways . Vacquinol-1 specifically induces human glioblastoma cell (GC) death, attenuates tumor progression and prolongs survival in a glioblastoma multiforme (GBM) mouse model . Vacquinol-1 also induces apoptosis in hepatocellular carcinoma (HCC)cell .
    Vacquinol-1
  • HY-19345A
    Vacquinol-1 dihydrochloride

    NSC13316 dihydrochloride

    		 p38 MAPK Cancer
    Vacquinol-1 (NSC13316) dihydrochloride is a MKK4-specific activator that activates MAPK pathways . Vacquinol-1 dihydrochloride specifically induces human glioblastoma cell (GC) death, attenuates tumor progression and prolongs survival in a glioblastoma multiforme (GBM) mouse model . Vacquinol-1 dihydrochloride also induces apoptosis in hepatocellular carcinoma (HCC)cell .
    Vacquinol-1 dihydrochloride
  • HY-135644
    Rencofilstat

    CRV431

    		 Cyclophilin Sirtuin Nuclear Factor of activated T Cells (NFAT) Interleukin Related Cancer
    Rencofilstat (CRV431) is an orally active pan-cyclophilin inhibitor with IC50 values of 2.5 nM, 3.1 nM, 2.8 nM, 7.3 nM for Cyp A, CypB, Cyp D and Cyp G, respectively. Rencofilstat reduces fibrosis and tumor growth in models of chronic liver disease. Rencofilstat can be used for the study of nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma and viral hepatitis-induced liver disease .
    Rencofilstat
  • HY-P99159
    Ivuxolimab

    		Interleukin Related Cancer
    Ivuxolimab is a fully human IgG2 agonist targeting OX40 (CD134), which selectively binds to the OX40 receptor on the surface of activated CD4 + and CD8 + T cells without inducing antibody-dependent cytotoxicity. Ivuxolimab can promote T cell proliferation, survival and cytokine (such as IFN-γ, IL-2) secretion, inhibit regulatory T cell function, and enhance anti-tumor immune response. Ivuxolimab can be used in the study of melanoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, etc .
    Ivuxolimab
  • HY-119398
    Lanuginosine

    		Amyloid-β Cholinesterase (ChE) Apoptosis Neurological Disease Cancer
    Lanuginosine is an alkaloid. Lanuginosine can be isolated from the stems of Xylopia laevigata (Annonaceae) and the leaves of Magnolia grandiflora. Lanuginosine induces Apoptosis. Lanuginosine inhibits AChE (IC50: 10.9 μM). Lanuginosine inhibits Aβ aggregation. Lanuginosine exhibits anticancer activity against hepatocellular carcinoma, human promyelocytic leukemia, human chronic myeloid leukemia, melanoma, and brain tumors. Lanuginosine can be used in the research of Alzheimer's disease .
    Lanuginosine
  • HY-N6623R
    Malvidin-3-galactoside chloride (Standard)

    		Reference Standards Apoptosis Endogenous Metabolite Reactive Oxygen Species (ROS) Cancer
    Malvidin-3-galactoside (chloride) (Standard) is the analytical standard of Malvidin-3-galactoside (chloride). This product is intended for research and analytical applications. Malvidin-3-galactoside chloride, an anthocyanin monomer, induces hepatocellular carcinoma (HCC) cells cycle arrest and apoptosis. Malvidin-3-galactoside chloride inhibits the production and accumulation of ROS. Malvidin-3-galactoside chloride has anti-tumor function .
    Malvidin-3-galactoside chloride (Standard)
  • HY-115581
    Thymidine 3',5'-disphosphate

    Deoxythymidine 3′,5′-diphosphate; pdTp

    		 Apoptosis Cancer
    Thymidine 3',5'-disphosphate (Deoxythymidine 3′,5′-diphosphate; pdTp) is a selective small molecule inhibitor of staphylococcal nuclease and tudor domain containing 1 (SND1, the miRNA regulatory complex RISC subunit) and inhibits SND1 activity. Thymidine 3',5'-disphosphate exhibits anti-tumor efficacy in vivo .
    Thymidine 3',5'-disphosphate
  • HY-115581A
    Thymidine 3',5'-diphosphate tetrasodium

    Deoxythymidine 3′,5′-diphosphate tetrasodium; pdTp tetrasodium

    		 Apoptosis MicroRNA Cancer
    Thymidine 3',5'-diphosphate (Deoxythymidine 3′,5′-diphosphate) tetrasodium is a selective inhibitor of staphylococcal nuclease and tudor domain containing 1 (SND1, the MicroRNA regulatory complex RISC subunit) and [3,5- 2H2] tyrosyl nuclease. Thymidine 3',5'-diphosphate tetrasodium has anti-tumor activity and can also be used as a catalyst in biochemical reactions .
    Thymidine 3',5'-diphosphate tetrasodium
  • HY-119618
    R1498

    		Endogenous Metabolite Cancer
    R1498 is a multi-target kinase inhibitor with anti-angiogenic and anti-proliferative activities. R1498 mainly targets targets such as Aurora kinase and VEGFR2, which are associated with tumor development. R1498 showed moderate in vitro growth inhibition in a variety of tumor cells, with IC50 values in the micromolar range. R1498 showed anti-tumor efficacy superior to sorafenib in a variety of gastric cancer and hepatocellular carcinoma xenograft models, with tumor growth inhibition rates exceeding 80%, and tumor shrinkage was observed in some models. R1498 showed a 10-30% tumor shrinkage rate in three xenograft models derived from human primary gastric cancer tumors, further demonstrating its inhibitory potential. R1498 effectively inhibited Aurora A activity in vivo and reduced tumor vascularization .
    R1498
  • HY-172874
    TDO-IN-2

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    TDO-IN-2 (Compound 5c) is an orally active TDO inhibitor (IC50: 1.25 μM). TDO-IN-2 has antitumor activity in the Hepa1-6 hepatocellular carcinoma allograft mouse model. TDO-IN-2 has synergistic effects with the PD-1/PD-L1 inhibitor BMS-202 (HY-19745) and can be used to study tumor immune tolerance .
    TDO-IN-2
  • HY-177268
    Anticancer agent 277

    		Apoptosis Reactive Oxygen Species (ROS) PARP Caspase Akt Cancer
    Anticancer agent 277 (Compound 4a) is an anticancer agent. Anticancer agent 277 has cytotoxic activities against cancer cells. Anticancer agent 277 significantly inhibits hepatocellular carcinoma cells proliferation via arresting S and G2/M phase cell cycle and induces apoptosis by inducing ROS production and elevating apoptosis-related proteins expression. Anticancer agent 277 potently inhibits tumor growth in HepG2 xenograft mice model .
    Anticancer agent 277
  • HY-162679
    c-Met degrader-1

    		c-Met/HGFR Apoptosis Cancer
    c-Met degrader-1 (Compound H11) is an orally active c-Met degrader (through the ubiquitin proteasome system). c-Met degrader-1 has anti-hepatocellular carcinoma activity (HCC) and inhibits tumor growth in MHCC97H xenografts. c-Met degrader-1 inhibits HCC cell growth, arrests cell cycle, and induces apoptosis. c-Met degrader-1 may overcome resistance to type Ib inhibitors .
    c-Met degrader-1
  • HY-151461
    CHNQD-01255

    		Arf Family GTPase Cancer
    CHNQD-01255 is an orally active Arf-GEFs inhibitor with potent anti-hepatocellular carcinoma (HCC) efficacy .
    CHNQD-01255
  • HY-W587938
    γ-Eudesmol

    (+)-γ-Eudesmol

    		 Apoptosis Cancer
    γ-Eudesmol ((+)-γ-Eudesmol) is a mitochondrial-mediated apoptosis inducer. γ-Eudesmol binds mitochondrial membrane proteins, triggering depolarization of mitochondrial membrane potential and activating caspase cascades. γ-Eudesmol demonstrates cytotoxicity against multiple tumor cell lines (e.g., HepG2, B16-F10) with IC50 values ranging from 8.86-15.15 μg/mL. γ-Eudesmol is promising for research of cancers, such as hepatocellular carcinoma and melanoma .
    γ-Eudesmol
  • HY-N1213
    Sprengerinin C

    		Others Cancer
    Sprengerinin is a potential angiogenesis inhibitor. Sprengerinin exerts anti-tumorigenic effects in vitro .
    Sprengerinin C
  • HY-P5372
    Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2

    		Protease Activated Receptor (PAR) Cancer
    Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2, a bioactive peptide, is a selective Protease activating receptor 1 (PAR-1) agonist over PAR-2. PAR-1 belongs to a subfamily of G-protein coupled receptors and is known to mediate the cellular effects of thrombin. In addition to its varied cellular effects of thrombin, PAR-1 has also been shown to coordinate with PAR-4 and regulate thrombin-induced hepatocellular carcinoma harboring thrombin formation within the tumor environment classified as 'coagulation type' .
    Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2
  • HY-P5372A
    Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2 TFA

    		Protease Activated Receptor (PAR) Cancer
    Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2 TFA, a bioactive peptide, is a selective Protease activating receptor 1 (PAR-1) agonist over PAR-2. PAR-1 belongs to a subfamily of G-protein coupled receptors and is known to mediate the cellular effects of thrombin. In addition to its varied cellular effects of thrombin, PAR-1 has also been shown to coordinate with PAR-4 and regulate thrombin-induced hepatocellular carcinoma harboring thrombin formation within the tumor environment classified as 'coagulation type' .
    Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2 TFA
  • HY-175646
    AGPAT4-IN-1

    		Acyltransferase mTOR Ribosomal S6 Kinase (RSK) Apoptosis Cancer
    AGPAT4-IN-1 (Compound CL26) is a covalent AGPAT4 inhibitor with an IC50 of 795 nM. AGPAT4-IN-1 covalently binds to AGPAT4 at Cys 228 and significantly inhibits acyltransferase activity, LPA-to-PA conversion and downstream mTOR/S6K pathways. AGPAT4-IN-1 sensitizes hepatocellular carcinoma (HCC) tumors to Sorafenib (HY-10201) and significantly induces apoptosis with a synergistic response. AGPAT4-IN-1 has antitumor activity and reduces tumorigenicity and stemness in HCC xenograft mouse models .
    AGPAT4-IN-1
  • HY-178018
    D574-0246

    iOXCT1

    		 Mitochondrial Metabolism Cancer
    D574-0246 is a dual-activity inhibitor of OXCT1, inhibiting both the ketolytic and succinyltransferase activities of OXCT1. D574-0246 reduces substrate-specific (LACTB K284) and global protein succinylation and decreases OXCT1 ketolytic activity in HepG2 cells. D574-0246 inhibits the viability of HCC cells (IC50: 16.49 μM in PLC cells, 6.656 μM in HepG2 cells). D574-0246 exerts anti-tumor efficacy in nude mice bearing OXCT1-overexpressing HepG2 xenograft tumors. D574-0246 can be used for the study of hepatocellular carcinoma (HCC) .
    D574-0246
  • HY-113081R
    1-Methyladenosine (Standard)

    		Reference Standards Endogenous Metabolite PPAR Hedgehog Cancer
    1-Methyladenosine (Standard) is the analytical standard of 1-Methyladenosine. This product is intended for research and analytical applications. 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis . In Vitro:Compared to surrounding tumor tissues, 1-methyladenosine methylation in RNA is aberrantly elevated in hepatocellular carcinoma (HCC) cell lines and liver cancer stem cells (CSCs). Methylated 1-methyladenosine can promote cholesterol synthesis and activate the Hedgehog signaling pathway by enhancing the translation of PPARδ in liver CSCs, ultimately driving the self-renewal and tumorigenesis of liver cancer stem cells .
    1-Methyladenosine (Standard)
  • HY-111126
    K67
    1 Publications Verification

    		 p62 Keap1-Nrf2 Cancer
    K67 is a selective the interaction between Keap1 and S349 phosphorylated p62 inhibitor, with an IC50 of 1.5 μM. K67 has a weaker inhibitory effect on the interaction between Keap1 and Nrf2 (IC50 is 6.2 μM). K67 competitively binds to the binding site of Keap1 with p-p62, blocking the abnormal activation of the p62-dependent Nrf2 pathway. K67 inhibits tumor cell proliferation and enhances the sensitivity of hepatocellular carcinoma (HCC) to chemotherapeutic drugs by restoring Keap1-mediated ubiquitination and degradation of Nrf2 .
    K67
  • HY-W011434
    Triglycidyl isocyanurate

    TGIC

    		 MDM-2/p53 Apoptosis Inflammation/Immunology Cancer
    Triglycidyl isocyanurate (TGIC; Teroxirone) is a triazene triepoxide with antiangiogenic and antineoplastic activities. Triglycidyl isocyanurate inhibits the growth of non-small-cell-lung cancer cells via?p53 activation. Triglycidyl isocyanurate induces cell apoptosis. Triglycidyl isocyanurate can be used for cancer research .
    Triglycidyl isocyanurate
  • HY-174450
    KMT9-IN-1

    		Epigenetic Reader Domain Cancer
    KMT9-IN-1 (Compound 8) is a KMT9 inhibitor and the ethyl ester prodrug of compound 7b. KMT9-IN-1 releases the active form 7b via esterases in cells. KMT9-IN-1 targets KMT9 in cells and reduces H4K12me1 levels. KMT9-IN-1 has antitumor activity against colon cancer. KMT9-IN-1 can be used in the research of prostate cancer and hepatocellular carcinoma .
    KMT9-IN-1
  • HY-174451
    KMT9-IN-2

    		Epigenetic Reader Domain Cancer
    KMT9-IN-2 (Compound 7b) is an active form of a KMT9 inhibitor (Kd of 10 nM). KMT9-IN-2 can be used in the research of colon cancer .
    KMT9-IN-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: